Regeneron Pharmaceuticals Inc (REGN) Buy,…

Regeneron Pharmaceuticals Inc (REGN)

608.50

-1.44 (0.24%)

as of Jun 18, 2026, 8:51:22 pm Market Open.

40 watching

BUY

An analyst upgraded this to $1,025, a very long way to go. He's gained 40% in this himself. It's reasonable at a 24x PE and enjoys momentum. Sees nothing to derail this.

DON'T BUY

The momentum is waning, and last quarter revenue growth was only 14%. They're coming to the end of the road.

BUY

Shares are down in the past 24 hours due to a delay in a drug approval. But another drug remains strong in sales, and they have double-digit in oncology drugs in trials. A great science company.

WEAK BUY

A quality company. Trades at 17x. The FDA is delaying approval of a drug, but that is correctable because the issue isn't about safety or efficacy.

BUY

Trades at 19x earnings, but have a huge drug pipeline.

BUY

Was upgraded today. He regrets not owning it. Great managers. Owning a biotech ETF like XBI is fine for risk management. Healthcare is recession-resistant and he loves it.

HOLD

She wishes that today's upgrade had come earlier. 2023 earnings will be flat, not great, but they have some new drugs will drive earnings in the future. This stock could do nothing for a while, but nothing wrong to hold it; earnings may stay flat.

STRONG BUY

His favourite stock in his favourite sector. It is up 18% YTD.

BUY

It trades at 13x earnings. Their pipeline is really good but was under pressure given drug pricing issues. This has outperformed the market this year. They have a strong pipeline of drugs and trades at an attractive valuation.

BUY

Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron.

HOLD

Large cap biotech. Its two franchises are dominant: macular degeneration and atopic dermatitis. One of the best at R&D. Proven ability to execute. One of the better growth profiles for next 3-5 years. Bit of volatility around reimbursement. Decent valuation. No dividend.

COMMENT

They report Friday. Sells at 11x earnings. They have drugs for asthma and other illnesses.

BUY

On Monday, they host an investors' event to showcase their work in RNA-based therapies and gene editing. Though it's a biotech, REGN is profitable and trades at a low PE. It trades on earnings and not future sales. If they tell a great story next week, he expects this stock to break out to an all-time high.

BUY

Not only REGN, but all healthcare stocks, like Bristol-Myers and Merck, have been under pressure. REGN is a great stock and worth holding long-term.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 23/20, Up 9.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with REGN has triggered its stop at $565. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment gain of 15%.

Showing 1 to 15 of 28 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Regeneron Pharmaceuticals Inc (REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc stock symbol?

Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol REGN (previously REGN-Q on Stockchase) on the NASDAQ (REGN). It is usually referred to as NASDAQ:REGN or REGN

Is Regeneron Pharmaceuticals Inc a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on REGN (previously REGN-Q on Stockchase) on Stockchase. Read the latest expert commentary for Regeneron Pharmaceuticals Inc.

Is Regeneron Pharmaceuticals Inc a good investment or a top pick?

Regeneron Pharmaceuticals Inc was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2021-10-05. Read the latest stock experts ratings for Regeneron Pharmaceuticals Inc.

Why is Regeneron Pharmaceuticals Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Regeneron Pharmaceuticals Inc.

Is Regeneron Pharmaceuticals Inc worth watching?

Regeneron Pharmaceuticals Inc is followed by 40 investors on Stockchase and is a trending stock that is worth watching.

What is Regeneron Pharmaceuticals Inc stock price?

On 2026-06-18, Regeneron Pharmaceuticals Inc (REGN) stock closed at a price of $608.50.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Regeneron Pharmaceuticals Inc (REGN)